{"id":"carboplatin-etoposide-thalidomide","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_fixedAt":"2026-03-30T13:30:33.667716","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carboplatin is a platinum-based alkylating agent that cross-links DNA and prevents replication. Etoposide is a topoisomerase II inhibitor that causes DNA strand breaks. Thalidomide enhances T-cell proliferation and NK cell activation while inhibiting tumor necrosis factor-alpha and angiogenesis. Together, these agents provide multi-modal cytotoxic and immunomodulatory effects against cancer cells.","oneSentence":"This combination uses carboplatin and etoposide as chemotherapy agents to damage cancer cell DNA, while thalidomide acts as an immunomodulator and anti-angiogenic agent to enhance anti-tumor immunity and inhibit blood vessel formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:56.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (phase 3 investigation)"}]},"_fixedFields":["pubmed(7)"],"trialDetails":[{"nctId":"NCT00061919","phase":"PHASE3","title":"Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University College, London","startDate":"2003-04","conditions":"Lung Cancer","enrollment":724}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"recentPublications":[{"date":"2012 Mar 13","pmid":"22353811","title":"Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.","journal":"British journal of cancer"},{"date":"2009 Dec 2","pmid":"19858426","title":"Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.","journal":"Journal of the National Cancer Institute"},{"date":"2009 Aug 5","pmid":"19608997","title":"Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.","journal":"Journal of the National Cancer Institute"},{"date":"2007","pmid":"17927281","title":"Modern management of small-cell lung cancer.","journal":"Drugs"},{"date":"2008 Mar","pmid":"17920723","title":"Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer.","journal":"Lung cancer (Amsterdam, Netherlands)"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Carboplatin, etoposide & thalidomide","genericName":"Carboplatin, etoposide & thalidomide","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses carboplatin and etoposide as chemotherapy agents to damage cancer cell DNA, while thalidomide acts as an immunomodulator and anti-angiogenic agent to enhance anti-tumor immunity and inhibit blood vessel formation. Used for Multiple myeloma (phase 3 investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}